| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Department of Pathology, Harborview Medical Center, University of Washington, Seattle, Washington; 2 CombiMatrix Corporation, Mukilteo, Washington; and 3 Fujirebio Diagnostics, Inc., Malvern, Pennsylvania
Requests for reprints: Ingegerd Hellstrom, Department of Pathology, Harborview Medical Center, University of Washington, 325 9th Avenue, Box 35 99 39, Seattle, WA 98104. Phone: 206-341-5908; Fax: 206-341-5909. E-mail: ihellstr{at}u.washington.edu
The mesothelin family comprises (at least) three variants and includes the precursor for megakaryocyte potentiating factor (MPF). Assaying soluble mesothelin-related protein (SMRP) molecules in serum and other body fluids from patients with certain cancers can provide diagnostically useful information. We have constructed fusion proteins of mesothelin variants 1, 2, and 3, made monoclonal antibodies, and investigated the binding specificity of these and three previously generated monoclonal antibodies to each of the three mesothelin variants. According to flow cytometry, the molecule that is most frequently expressed at the surface of cells from ovarian carcinomas and certain other tumors is mesothelin variant 1. Similarly, SMRP released into ascites from a patient with ovarian carcinoma was shown to have a molecular weight of 
40 kDa and, according to sequencing, to be variant 1. A published sandwich ELISA was shown to detect variants 1 and 3 and to be much more sensitive than a newly constructed ELISA, which detects only variant 3, the former being positive in 28 of 41 (68%) sera from patients with ovarian cancer as compared with 6 of 41 sera (15%). A standard curve was constructed to measure SMRP with a limit of detection of 200 pg/mL to facilitate future quantitative studies. (Cancer Epidemiol Biomarkers Prev 2006;15(5):1014–20) (Cancer Epidemiol Biomarkers Prev 2006;15(5):1014-1019)
This article has been cited by other articles:
|
|
 |
|
  K. A. Lowe, C. Shah, E. Wallace, G. Anderson, P. Paley, M. McIntosh, M. R. Andersen, N. Scholler, L. Bergan, J. Thorpe, et al. Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2480 - 2487. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hellstrom, E. Friedman, T. Verch, Y. Yang, J. Korach, J. Jaffar, E. Swisher, B. Zhang, G. Ben-Baruch, M. C.B. Tan, et al. Anti-Mesothelin Antibodies and Circulating Mesothelin Relate to the Clinical State in Ovarian Cancer Patients Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1520 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Scholler, K. A. Lowe, L. A. Bergan, A. V. Kampani, V. Ng, R. M. Forrest, J. D. Thorpe, J. A. Gross, B. M. Garvik, R. Drapkin, et al. Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA Clin. Cancer Res., May 1, 2008; 14(9): 2647 - 2655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Uehara, Y. Matsuoka, and A. Tsubura Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells Mol. Cancer Res., February 1, 2008; 6(2): 186 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Creaney, I. van Bruggen, M. Hof, A. Segal, A. W. Musk, N. de Klerk, N. Horick, S. J. Skates, and B. W. S. Robinson Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma Chest, October 1, 2007; 132(4): 1239 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y C G. Lee Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer? Thorax, July 1, 2007; 62(7): 561 - 562. [Full Text] [PDF]
|
|
|
|
|
|
J. Creaney, D. Yeoman, L. K Naumoff, M. Hof, A. Segal, A. W. Musk, N. De Klerk, N. Horick, S. J Skates, and B. W S Robinson Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma Thorax, July 1, 2007; 62(7): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-D. Grigoriu, A. Scherpereel, P. Devos, B. Chahine, M. Letourneux, P. Lebailly, M. Gregoire, H. Porte, M.-C. Copin, and P. Lassalle Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment Clin. Cancer Res., May 15, 2007; 13(10): 2928 - 2935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Beyer, R. D. Geschwindt, C. L. Glover, L. Tran, I. Hellstrom, K.-E. Hellstrom, M. C. Miller, T. Verch, W. J. Allard, H. I. Pass, et al. MESOMARKTM: A Potential Test for Malignant Pleural Mesothelioma Clin. Chem., April 1, 2007; 53(4): 666 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, T. K. Bera, M. C. Willingham, M. Onda, R. Hassan, D. FitzGerald, and I. Pastan Mesothelin Expression in Human Lung Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1571 - 1575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ho, M. Onda, Q.-c. Wang, R. Hassan, I. Pastan, and M. O. Lively Mesothelin is shed from tumor cells. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1751 - 1751. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
